Dr. Ming Wang is currently Vice President and Disease Area Leader of Diabetes/Metabolism at Janssen Pharmaceuticals of Johnson & Johnson. In this role, he is responsible for setting disease area strategies, making investment decisions and building a portfolio of assets for disease treatment and prevention. Previously, he was President and Chief Operating Officer and a member of the Board of Directors at Gan & Lee Pharmaceuticals, a biotech pioneer in China focused on insulin-based therapies with annual combined sales of ~$100 million in China, Latin America and Southeast Asia. Prior to that, Ming was Executive Director and Head of Diabetes Research at Amgen where he headed a group of ~50 scientists located on two research sites working on developing novel therapies for metabolic diseases. Before joining Amgen, Ming championed drug discovery programs in cardiovascular and metabolic diseases and managed corporate partnerships in Parke-Davis, Pfizer and Pharmacia.
Ming served on multiple advisory boards, including the Scientific Advisory Board (SAB) of Amgen Ventures ($100 million in management). Ming is a frequent speaker at scientific and drug discovery conferences and has 59 publications and a book entitled “Metabolic Syndrome: underlying mechanisms and drug therapies” (publisher: John Wiley & Sons, Inc.). Ming is also an adjunct faculty in the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco Schools of Pharmacy and Medicine. Ming holds a PhD in Biochemistry and a MBA in General management.